Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults.

Tamura MK, Pajewski NM, Bryan RN, Weiner DE, Diamond M, Van Buren P, Taylor A, Beddhu S, Rosendorff C, Jahanian H, Zaharchuk G; SPRINT Study Research Group..

Neurology. 2016 Mar 29;86(13):1208-16. doi: 10.1212/WNL.0000000000002527. Epub 2016 Feb 26.

2.

A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

SPRINT Research Group., Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT.

N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9.

3.

Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.

Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, Kennedy JA, Schimmer AD, Schuh AC, Yee KW, McLeod JL, Doedens M, Medeiros JJ, Marke R, Kim HJ, Lee K, McPherson JD, Hudson TJ; HALT Pan-Leukemia Gene Panel Consortium., Brown AM, Yousif F, Trinh QM, Stein LD, Minden MD, Wang JC, Dick JE.

Nature. 2014 Feb 20;506(7488):328-33. doi: 10.1038/nature13038. Epub 2014 Feb 12. Erratum in: Nature. 2014 Apr 17;508(7496):420. Yousif, Fouad [added].

4.

Cancer patient perceptions on the ethical and legal issues related to biobanking.

Master Z, Claudio JO, Rachul C, Wang JC, Minden MD, Caulfield T.

BMC Med Genomics. 2013 Mar 8;6:8. doi: 10.1186/1755-8794-6-8.

5.

Stem cell tourism and Canadian family physicians.

Caulfield T, Zarzeczny A; Toronto Stem Cell Working Group..

Can Fam Physician. 2012 Apr;58(4):365-8, e182-5. English, French. No abstract available.

6.

Exemestane for breast-cancer prevention in postmenopausal women.

Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H; NCIC CTG MAP.3 Study Investigators..

N Engl J Med. 2011 Jun 23;364(25):2381-91. doi: 10.1056/NEJMoa1103507. Epub 2011 Jun 4. Erratum in: N Engl J Med. 2011 Oct 6;365(14):1361.

7.

A targeted association study in systemic lupus erythematosus identifies multiple susceptibility alleles.

Budarf ML, Goyette P, Boucher G, Lian J, Graham RR, Claudio JO, Hudson T, Gladman D, Clarke AE, Pope JE, Peschken C, Smith CD, Hanly J, Rich E, Boire G, Barr SG, Zummer M; GenES Investigators., Fortin PR, Wither J, Rioux JD.

Genes Immun. 2011 Jan;12(1):51-8. doi: 10.1038/gene.2010.47. Epub 2010 Oct 21.

PMID:
20962850
8.

Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents.

Cooper GS, Wither J, Bernatsky S, Claudio JO, Clarke A, Rioux JD; CaNIOS GenES Investigators., Fortin PR.

Rheumatology (Oxford). 2010 Nov;49(11):2172-80. doi: 10.1093/rheumatology/keq214. Epub 2010 Jul 31.

9.

Cutting Edge: Importance of IL-6 and cooperation between innate and adaptive immune receptors in cellular vaccination with B lymphocytes.

Vanden Bush TJ, Buchta CM, Claudio J, Bishop GA.

J Immunol. 2009 Oct 15;183(8):4833-7. doi: 10.4049/jimmunol.0900968.

10.

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial.

Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R; CV181-040 Investigators..

Int J Clin Pract. 2009 Sep;63(9):1395-406. doi: 10.1111/j.1742-1241.2009.02143.x. Epub 2009 Jul 15. Erratum in: Int J Clin Pract. 2010 Jan;64(2):277.

11.

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R; CV181-039 Investigators..

Diabetes Obes Metab. 2009 Jun;11(6):611-22. doi: 10.1111/j.1463-1326.2009.01056.x.

PMID:
19515181
12.

The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort.

Peschken CA, Katz SJ, Silverman E, Pope JE, Fortin PR, Pineau C, Smith CD, Arbillaga HO, Gladman DD, Urowitz M, Zummer M, Clarke A, Bernatsky S, Hudson M; Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS)..

J Rheumatol. 2009 Jun;36(6):1200-8. doi: 10.3899/jrheum.080912. Epub 2009 Apr 15.

PMID:
19369456
13.

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr.

JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.

14.

The prevalence and accuracy of self-reported history of 11 autoimmune diseases.

Cooper GS, Wither J, McKenzie T, Claudio JO, Bernatsky S, Fortin PR; CaNIOS GenES Investigators..

J Rheumatol. 2008 Oct;35(10):2001-4. Epub 2008 Sep 1.

PMID:
18785310
15.

Reduced proportions of natural killer T cells are present in the relatives of lupus patients and are associated with autoimmunity.

Wither J, Cai YC, Lim S, McKenzie T, Roslin N, Claudio JO, Cooper GS, Hudson TJ, Paterson AD, Greenwood CM, Gladman D, Pope J, Pineau CA, Smith CD, Hanly JG, Peschken C, Boire G; CaNIOS Investigators., Fortin PR.

Arthritis Res Ther. 2008;10(5):R108. doi: 10.1186/ar2505. Epub 2008 Sep 10.

16.

Expression and mutation status of candidate kinases in multiple myeloma.

Claudio JO, Zhan F, Zhuang L, Khaja R, Zhu YX, Sivananthan K, Trudel S, Masih-Khan E, Fonseca R, Bergsagel PL, Scherer SW, Shaughnessy J, Stewart AK.

Leukemia. 2007 May;21(5):1124-7. Epub 2007 Mar 8. No abstract available. Erratum in: Leukemia.2008 Apr;22(4): 889-90.

PMID:
17344920
17.

MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma.

Masih-Khan E, Trudel S, Heise C, Li Z, Paterson J, Nadeem V, Wei E, Roodman D, Claudio JO, Bergsagel PL, Stewart AK.

Blood. 2006 Nov 15;108(10):3465-71. Epub 2006 Jul 18.

18.

Gastrin-releasing peptide receptor antagonist effects on an animal model of sepsis.

Dal-Pizzol F, Di Leone LP, Ritter C, Martins MR, Reinke A, Pens Gelain D, Zanotto-Filho A, de Souza LF, Andrades M, Barbeiro DF, Bernard EA, Cammarota M, Bevilaqua LR, Soriano FG, Cláudio J, Moreira F, Roesler R, Schwartsmann G.

Am J Respir Crit Care Med. 2006 Jan 1;173(1):84-90. Epub 2005 Sep 28.

PMID:
16192447
19.

Analysis of PTEN deletions and mutations in multiple myeloma.

Chang H, Qi XY, Claudio J, Zhuang L, Patterson B, Stewart AK.

Leuk Res. 2006 Mar;30(3):262-5. Epub 2005 Aug 19.

PMID:
16112193
20.

Advances in myeloma genetics and prospects for pharmacogenomic testing in multiple myeloma.

Claudio JO, Stewart AK.

Am J Pharmacogenomics. 2005;5(1):35-43. Review.

PMID:
15727487

Supplemental Content

Loading ...
Support Center